The prolyl oligopeptidase inhibitor KYP‑2047 is not readily bioavailable to bloodstream form trypanosomes and human myelocytic leukemia cells. Journal of Pharmaceutical Negative Results [Internet]. 2015 Jan. 28 [cited 2026 May 14];6(1):7-10. Available from: https://mail.pnrjournal.com/index.php/home/article/view/84